Scientists established RBM39/MLL1 as a major contributor to the abnormal epigenetic landscape in breast cancer and laid the foundation for peptide-mediated cancer-specific therapy based on disruption of RBM39 epigenomic functions.
[Cell Reports]
Sorry, but the selected Zotpress account can't be found.